1. Search Result
Search Result
Results for "

PPARs

" in MedChemExpress (MCE) Product Catalog:

411

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

91

Natural
Products

42

Isotope-Labeled Compounds

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143239

    PPAR Metabolic Disease
    PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC50 values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .
    PPARα/γ agonist 1
  • HY-N0234
    Bavachinin
    3 Publications Verification

    7-O-Methylbavachin; Bavachinin A

    Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
    Bavachinin
  • HY-125716

    PPAR Metabolic Disease
    DRF-2519 (free base) is a dual activator of PPAR α and PPAR γ. DRF-2519 (free base) has antidiabetic and hypolipidemic activity .
    DRF-2519 free base
  • HY-120255A

    PPAR Metabolic Disease
    17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and PPARδ .
    17(S)-HDHA
  • HY-160003

    PPAR Metabolic Disease
    PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC50 more than 10 μM for LPA3 receptor .
    PPARγ agonist 9
  • HY-162320

    PPAR Metabolic Disease
    PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .
    PPARγ agonist 12
  • HY-103034

    PPAR Metabolic Disease
    Sipoglitazar is an orally active agonist of PPAR. Sipoglitazar can be used to study diabetes .
    Sipoglitazar
  • HY-107333

    PPAR Metabolic Disease
    Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity .
    Cinoxate
  • HY-143862

    PPAR Metabolic Disease
    Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .
    Pparδ agonist 7
  • HY-143863

    PPAR Metabolic Disease
    Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .
    PPARδ agonist 8
  • HY-N0234R

    Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .
    Bavachinin (Standard)
  • HY-N11924

    AMPK PPAR Metabolic Disease
    Foenumoside B is a triterpene saponin isolated from Lysimachia foenum-graecum. Foenumoside B activates AMPK signaling, inhibits PPARγ-induced adipogenesis, and shifts lipid metabolism toward lipolysis. Foenumoside B can be used in the study of obesity and obesity-related metabolic diseases .
    Foenumoside B
  • HY-N1029

    Mangiferitin

    Glucosidase PPAR Infection Inflammation/Immunology Cancer
    Norathyriol (Mangiferitin) is a natural metabolite of Mangifera. Norathyriol inhibits α-glucosidase in a noncompetitive manner with an IC50 of 3.12 μM . Norathyriol inhibits PPARα, PPARβ, and PPARγ with IC50s of 92.8 µM, 102.4 µM, and 153.5 µM, respectively . Antioxidant, anticancer, antimicrobial, anti-inflammatory, anti-bacterial activities.
    Norathyriol
  • HY-130319A

    PPAR Cardiovascular Disease Metabolic Disease
    9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
    9-HEPE
  • HY-117431

    PGB3

    PPAR Endogenous Metabolite Metabolic Disease
    Prostaglandin B3 (PGB3) is a member of the class of prostaglandins B and a secondary alcohol. PGB3 exhibits a rather low affinity to human PPARγ with a Ki value greater than 1 mM compared with Ki values of 26.28 ± 8.7 μM for PGB1 and 77 ± 37.7 μM for PGB2 .
    Prostaglandin B3
  • HY-B0637
    Bezafibrate
    5+ Cited Publications

    BM15075

    PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate
  • HY-13928
    GW0742
    10+ Cited Publications

    GW610742

    PPAR Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742
  • HY-14817

    PPM 204

    PPAR Metabolic Disease
    Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ .
    Indeglitazar
  • HY-B0287
    Clofibrate
    2 Publications Verification

    PPAR Metabolic Disease
    Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
    Clofibrate
  • HY-144111

    PPAR Inflammation/Immunology
    PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC50=7.0 nM; PPARδ EC50=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC50=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .
    PPARα/δ agonist 1
  • HY-163547

    PPAR Inflammation/Immunology
    PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC50 values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .
    PPAR agonist 5
  • HY-B0637S

    PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d6
  • HY-B0637S1

    BM15075-d4

    Isotope-Labeled Compounds PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d4
  • HY-16995
    Pirinixic acid
    15+ Cited Publications

    Wy-14643

    PPAR Metabolic Disease Inflammation/Immunology
    Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
    Pirinixic acid
  • HY-B0637R

    PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate (Standard)
  • HY-162123

    PPAR Inflammation/Immunology
    PPARα/γ agonist 4 (compound 14) is a potent PPARα and PPARδ agonist with EC50s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/γ agonist 4 shows anti-inflammatory effects .
    PPARα/δ agonist 2
  • HY-148922

    PPAR Metabolic Disease
    PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .
    PPARα/γ agonist 2
  • HY-163443

    PPAR Others
    PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC50s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .
    PPAR agonist 4
  • HY-139177

    PPAR Cardiovascular Disease
    PPARα agonist 2 (compound 4u) is a potent and selective PPARα agonist with an EC50 of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .
    PPARα agonist 2
  • HY-B0287S

    PPAR Metabolic Disease
    Clofibrate-d4 is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
    Clofibrate-d4
  • HY-20019

    PPAR Metabolic Disease
    L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
    L-165041
  • HY-13861
    GW7647
    15+ Cited Publications

    PPAR Cardiovascular Disease
    GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
    GW7647
  • HY-147757

    PPAR Metabolic Disease
    PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with Ki values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC50 of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .
    PPARγ/δ modulator 1
  • HY-10678
    BMS-687453
    2 Publications Verification

    PPAR Cardiovascular Disease
    BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
    BMS-687453
  • HY-106266

    Carfloglitazar

    PPAR Metabolic Disease
    Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.
    Chiglitazar
  • HY-B0287R
    Clofibrate (Standard)
    2 Publications Verification

    PPAR Metabolic Disease
    Clofibrate (Standard) is the analytical standard of Clofibrate. This product is intended for research and analytical applications. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
    Clofibrate (Standard)
  • HY-147705

    PPAR Metabolic Disease
    PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC50 of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC50 of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects .
    PPARγ phosphorylation inhibitor 1
  • HY-17618A

    Rac-K13675

    PPAR Inflammation/Immunology
    Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate
  • HY-121448

    PPAR Cardiovascular Disease Metabolic Disease
    GW409544 is a potent PPARα and PPARγ activator, with EC50 values of 2.3 nM and 0.28 nM for PPARα and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases .
    GW409544
  • HY-15725
    CDDO-Im
    5+ Cited Publications

    RTA-403; TP-235; CDDO-Imidazolide

    Keap1-Nrf2 PPAR Ferroptosis Cancer
    CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ .
    CDDO-Im
  • HY-U00340

    PPAR Metabolic Disease
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-17444

    PPAR Metabolic Disease Cancer
    Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that is more potent on PPARγ than on PPARα, with EC50s of 13.4 μM and 3.6 μM for rat PPARα and human PPARα, respectively, and approximately 0.2 μM for both rat and human PPARγ. Tesaglitazar induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats .
    Tesaglitazar
  • HY-106278

    PPAR Metabolic Disease
    GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .
    GW 590735
  • HY-146480

    PPAR Cancer
    PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .
    PPARγ agonist 5
  • HY-146482

    PPAR Cancer
    PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases .
    PPARγ agonist 6
  • HY-121798

    PPAR Metabolic Disease
    TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .
    TZD18
  • HY-146438

    PPAR Cancer
    PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .
    PPARγ agonist 3
  • HY-100428

    MCC-555; Isaglitazone

    PPAR Metabolic Disease
    Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .
    Netoglitazone
  • HY-16578
    GW9662
    Maximum Cited Publications
    137 Publications Verification

    PPAR Cancer
    GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
    GW9662
  • HY-19383

    PTP 112

    Phosphatase IKK PPAR Metabolic Disease
    Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
    Ertiprotafib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: